All In MedTech

Device Trial Radar · NCT05732818

Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nuclectomy 3

Clinical Investigation Plan First in Human Trial Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nuclectomy "LOPAIN3"

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

50

Planned (sponsor's estimate)

Start

Jun 16, 2023

Primary completion

Sep 16, 2027

Study completion Jun 16, 2028

Sponsor

Lead sponsor
Spinal Stabilization TechnologiesNot on our public-company list
Sponsor type
Industry
Collaborators
Raylytic GmbH
First posted
Feb 17, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a First in Human, prospective, multi-center clinical study intended to collect safety and performance information for the Spinal Stabilization Technologies PerQdisc® Nucleus Replacement System and procedure concurrently following a successful discectomy using a minimally invasive posterolateral (MIPL) approach. Patients that are at least 21 years or older, presenting with symptomatic radiculopathy from a focal lumbar disc herniation that requires surgical decompression will be included in this study.

Conditions

  • Back Pain With Radiation
  • Radiculopathy
  • Back Pain
  • Disc Herniation
  • Herniated Nucleus Pulposus
  • Herniated Disc
  • Disc Injury
  • Disk Herniated Lumbar

Interventions

  • PerQdisc Nucleus Replacement SystemDevice

    Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Number of Patients with Serious Adverse Events related to the PerQdiscTime frame: 12 months

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Sanatorio Americano

    Asunción, Paraguay

  • Republican Specialized Scientific Practical Medical Center of Endocrinology named after Academician Y.Kh. Turakulova

    Tashkent, Tashkent, Uzbekistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.